{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE298nnn/GSE298290/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298290"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"T cells dressed up with a dual HLA-restricted TCR targeting Cathepsin G drive effective leukemia eradication","description":"Despite immunosensitivity, genetic heterogeneity, low mutational burden and lack of tumor-specific antigens hinder immunotherapy success for acute myeloid leukemia (AML). T cell receptors (TCRs) offer a promising route by targeting tumor-relevant intracellular antigens shared across AML subtypes; however human leukocyte antigen (HLA) restriction limits their potential. We identified a potent TCR capable of recognizing peptides of Cathepsin G (CTSG), a serine protease confined to neutrophil granules but aberrantly localized in the cytoplasm of leukemic blasts, when presented by HLA-A*24:02 and HLA-C*07:02, highly frequent alleles. Leveraging TCR gene-editing and CD8 co-receptor transduction, we engineered a robust T cell army, comprising cytotoxic CD8+ and CD4+CD8+ T lymphocytes with enhanced helper activity. Noticeably, CTSG-TCR T cells exhibited potent and specific cytotoxicity against primary AML blasts, culminating in complete in vivo disease eradication and a favorable safety profile. These results reveal the potential of dual restricted TCRs, and of CTSG-TCR T cells as powerful therapeutics for a broad AML patient population","dates":{"publication":"2026/10/06"},"accession":"GSE298290","cross_references":{"GSM":["GSM9011417","GSM9011416"],"GPL":["24676"],"GSE":["298290"],"taxon":["Homo sapiens"],"PMID":["[41980033]"]}}